Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. (PHIO), a Delaware corporation listed on the Nasdaq Capital Market, filed this Current Report on Form 8-K on May 11, 2023. The filing announces the release of financial results for the period ended March 31, 2023.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) containing the actual financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing text does not provide a clear value for these metrics.
Material Changes
No material changes versus the prior comparable period are detailed in this specific filing text, as the quantitative results are contained in the referenced press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release will not be treated as "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 11, 2023) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate based on the Q1 2023 results.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the company has announced any capital raise plans or liquidity events in the accompanying materials.